CompletedNot Applicable

YAG Vitreolysis for Floaters

52 participantsStarted 2015-02

Plain-language summary

This is a single-center, prospective randomized controlled trial evaluating the safety and efficacy of YAG vitreolysis versus sham for symptomatic Weiss ring due to posterior vitreous detachment.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Symptoms of floaters that correlate to the presence of a posterior vitreous detachment for at least 6 months
✓. Documented posterior vitreous detachment on clinical examination, OCT, and B scan
✓. Self-rating of visual disturbance by the floaters must be at least 4 on a 0-10 scale, with 0 being no symptoms to 10 being debilitating symptoms.
✓. Symptomatic Weiss ring (PVD) must be at least 3 mm away from the retina and 5 mm from the posterior lens capsule of the crystalline lens, as measured on B-scan. For pseudophakic patients, there is no minimum required distance from the intraocular lens.
✓. Able to position for the YAG laser procedure.
✓. Accept the risks of YAG laser including but not limited to retinal detachment, intraocular hemorrhage, retinal damage, cataract formation, optic nerve damage, inflammation, and irreversible loss of vision.
✓. Willing and able to comply with clinic visits and study-related procedures
✓. If the patient has two symptomatic eyes, only one eye can be randomized and included in the study.

Exclusion criteria

✕. Snellen best corrected visual acuity worse than 20/50 in the fellow eye
✕. History of retinal tear, retinal detachment, or uveitis in the study eye
✕. History of diabetic retinopathy, macular edema, retinal vein occlusion, or aphakia in the study eye
✕. History of glaucoma or high intraocular pressure defined as having a history of glaucoma surgery or currently taking two or more topical glaucoma medications in the study eye

What they're measuring

Subjective improvement in floater symptoms

Timeframe: 6 Months

Trial details

NCT IDNCT02897583

SponsorOphthalmic Consultants of Boston

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-08

View on ClinicalTrials.gov More Weiss Ring trials